Mammoth stakes IP claim to CRISPR diagnostic applications

With two newly issued patents covering key CRISPR systems for diagnostic applications, Mammoth strengthens its IP position as it pushes its CRISPR-based diagnostic platform closer to the clinic.

The CRISPR patent landscape hasn't been as controversial for diagnostics as therapeutics, but the parties at odds over therapeutics applications have each licensed IP rights to different diagnostics companies: Mammoth Biosciences (San Francisco, Calif.) has an exclusive license to IP from the University of California for diagnostic applications, while Sherlock Biosciences Inc. (Cambridge, Mass.) licensed exclusive rights to IP from the Broad Institute of MIT and Harvard (see "Mammoth Makes Dx CRISPR")...